title: Biogen's portfolio and research efforts in multiple sclerosis: an interview with Dr Ralph Kern.
abstract: Ralph Kern speaks to Laura Dormer, Commissioning Editor: Dr Ralph Kern is Senior Vice President and Head of Worldwide Medical at Biogen in Cambridge, MA, USA. In this role, he oversees Biogen's global therapeutic, regional and country medical teams, global medical operations, as well as medical research and scientific communications functions. Prior to joining Biogen, he was head of the Neuroscience Medical Unit at Novartis Pharmaceuticals Corporation and held various medical and commercial leadership roles at Genzyme Corporation. Prior to joining industry, he was a consultant neurologist at Mount Sinai Hospital and the University Health Network in Toronto, Ontario and was head of the neurology postgraduate academic program at the University of Toronto. Ralph completed neurology postgraduate training at McGill University and completed a masters of health administration from the Institute for Health Policy, Management and Evaluation at the University of Toronto. He is a member of the College of Physicians and Surgeons of Ontario and the Royal College of Physicians and Surgeons of Canada.
authors.affiliation: Worldwide Medical, Biogen, Cambridge, MA, USA.
authors.forename: Ralph
authors.initials: R
authors.lastname: Kern
mesh_terms: D035843:Biomedical Research; D002170:Canada; D006801:Humans; D007857:Leadership; D009103:Multiple Sclerosis / Q000628:therapy*
keywords: ECTRIMS; multiple sclerosis; therapeutics